Olanexidine

The problem of Gram-positive bacterial resistance continues to intensify globally, and the clinical treatment options for infections caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) are extremely limited. Oritavancin is a new type of bipyridine antibacterial drug. It targets the lipoteichoic acid synthesis process on the surface of bacterial cell membranes, destroys the integrity of bacterial cell membranes and inhibits cell wall synthesis, thereby exerting a rapid bactericidal effect, and has no cross-resistance with existing commonly used antibacterial drugs. Its indications are mainly acute bacterial skin and skin structure infections (ABSSSI) caused by sensitive Gram-positive bacteria in adult patients, and it can also be used as a treatment option for other drug-resistant Gram-positive bacterial infections, providing a new medication regimen for hospitalized patients with high incidence of drug-resistant bacterial infections and patients with low immune function.

According to public data, the global market size of anti-drug-resistant bacterial drugs has exceeded US$12 billion in 2023, among which the annual compound growth rate of new anti-Gram-positive bacterial drugs remains above 8%, which is higher than the growth rate of the overall antibacterial drug market. At present, the global market of oritavancin is still in the early stage of volume expansion. The original research product has not been included in the medical insurance catalogs of most countries, with a relatively high price, and there is sufficient space for generic drug development. At present, no generic drug of this variety has been approved in China, and only a small number of enterprises have started the declaration work of APIs and preparations, so the market competition pattern is relatively loose.

The original research enterprise of oritavancin is Melinta Therapeutics, and the original research trade name is Orbactiv. Its US compound patent expires in 2031, and its Chinese compound patent expires in 2032. The main dosage form approved for the original research is lyophilized powder for injection, with a specification of 400 mg per vial. It has been included in the FDA Reference Listed Drug Catalog, and has not yet been included in the *List of Chemical Drugs* of China. There are no oritavancin preparation products approved for marketing in China, and the CDE API Registration Platform has not yet disclosed a valid API registration number for this variety. (Data as of May 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of oritavancin impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All impurities meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the reference standard use needs of pharmaceutical enterprises in all stages of API R&D, quality research and registration declaration.